RNF7 and nonpapillary renal cell carcinoma: The potential clinical relevance of these findings was investigated by researching the effects of RNF7 on the sensitivity of ccRCC cells to sunitinib, a tyrosine kinase receptor inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) [38].